209 related articles for article (PubMed ID: 36249202)
1. Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectiveness.
Zeng X; Zhou Z; Luo X; Liu Q
Front Public Health; 2022; 10():977550. PubMed ID: 36249202
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China.
Zhao Z; Wang Y; Wu W; Yang Y; Du L; Dong H
JAMA Netw Open; 2022 May; 5(5):e2213634. PubMed ID: 35608858
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness and health impact of lung cancer screening with low-dose computed tomography for never smokers in Japan and the United States: a modelling study.
Kowada A
BMC Pulm Med; 2022 Jan; 22(1):19. PubMed ID: 34996423
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score.
Zhao Z; Gu S; Yang Y; Wu W; Du L; Wang G; Dong H
BMC Cancer; 2024 Jan; 24(1):73. PubMed ID: 38218803
[TBL] [Abstract][Full Text] [Related]
5. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation.
Snowsill T; Yang H; Griffin E; Long L; Varley-Campbell J; Coelho H; Robinson S; Hyde C
Health Technol Assess; 2018 Nov; 22(69):1-276. PubMed ID: 30518460
[TBL] [Abstract][Full Text] [Related]
6. Risk-based lung cancer screening in heavy smokers: a benefit-harm and cost-effectiveness modeling study.
Liu Y; Xu H; Lv L; Wang X; Kang R; Guo X; Wang H; Zheng L; Liu H; Guo L; Chen Q; Liu S; Qiao Y; Zhang S
BMC Med; 2024 Feb; 22(1):73. PubMed ID: 38369461
[TBL] [Abstract][Full Text] [Related]
7. Determining cost-effectiveness of lung cancer screening in urban Chinese populations using a state-transition Markov model.
Sun C; Zhang X; Guo S; Liu Y; Zhou L; Shi J; Wu N; Zhai Z; Liu G
BMJ Open; 2021 Jul; 11(7):e046742. PubMed ID: 34210726
[TBL] [Abstract][Full Text] [Related]
8. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.
Wattson DA; Hunink MG; DiPiro PJ; Das P; Hodgson DC; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):344-53. PubMed ID: 25104066
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
Jaine R; Kvizhinadze G; Nair N; Blakely T
Lung Cancer; 2018 Oct; 124():233-240. PubMed ID: 30268467
[TBL] [Abstract][Full Text] [Related]
10. Shall We Screen Lung Cancer With Low-Dose Computed Tomography? Cost-Effectiveness in Hungary.
Nagy B; Szilberhorn L; Győrbíró DM; Moizs M; Bajzik G; Kerpel-Fronius A; Vokó Z
Value Health Reg Issues; 2023 Mar; 34():55-64. PubMed ID: 36502786
[TBL] [Abstract][Full Text] [Related]
11. Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations.
Behr CM; Oude Wolcherink MJ; IJzerman MJ; Vliegenthart R; Koffijberg H
Pharmacoeconomics; 2023 Apr; 41(4):395-411. PubMed ID: 36670332
[TBL] [Abstract][Full Text] [Related]
12. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness of lung cancer screening worldwide: a systematic review].
Liu CC; Shi JF; Liu GX; Tang W; Zhang X; Li F; Wang L; Ma Y; Su K; Zhao SJ; Gao YB; Li N; Chen WQ; Wu N; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):218-226. PubMed ID: 30744276
[No Abstract] [Full Text] [Related]
14. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography.
Grover H; King W; Bhattarai N; Moloney E; Sharp L; Fuller L
Lung Cancer; 2022 Aug; 170():20-33. PubMed ID: 35700629
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness.
Goulart BH; Bensink ME; Mummy DG; Ramsey SD
J Natl Compr Canc Netw; 2012 Feb; 10(2):267-75. PubMed ID: 22308519
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of screening for lung cancer with low-dose computed tomography: a systematic literature review.
Puggina A; Broumas A; Ricciardi W; Boccia S
Eur J Public Health; 2016 Feb; 26(1):168-75. PubMed ID: 26370440
[TBL] [Abstract][Full Text] [Related]
18. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.
Kumar V; Cohen JT; van Klaveren D; Soeteman DI; Wong JB; Neumann PJ; Kent DM
Ann Intern Med; 2018 Feb; 168(3):161-169. PubMed ID: 29297005
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of lung cancer screening with low-dose computed tomography in an Iranian high-risk population.
Esmaeili MH; Seyednejad F; Mahboub-Ahari A; Ameri H; Abdollahzad H; Safaei N; Alinezhad F; Yousefi M
J Med Screen; 2021 Dec; 28(4):494-501. PubMed ID: 34039102
[TBL] [Abstract][Full Text] [Related]
20. Impact of low-dose CT screening for lung cancer on ethnic health inequities in New Zealand: a cost-effectiveness analysis.
McLeod M; Sandiford P; Kvizhinadze G; Bartholomew K; Crengle S
BMJ Open; 2020 Sep; 10(9):e037145. PubMed ID: 32973060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
